PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.45%
Revenue growth near Drug Manufacturers - Specialty & Generic median of 5.45%. Charlie Munger would verify if industry-standard growth is attractive.
6.69%
Cost growth near Drug Manufacturers - Specialty & Generic median of 6.69%. Charlie Munger would verify if industry cost structure is attractive.
2.54%
Gross profit growth 75-90% of Drug Manufacturers - Specialty & Generic median of 3.07%. John Neff would investigate improvement potential.
-2.77%
Margin decline while Drug Manufacturers - Specialty & Generic median is -2.65%. Seth Klarman would investigate competitive position.
-42.86%
R&D reduction while Drug Manufacturers - Specialty & Generic median is -10.68%. Seth Klarman would investigate competitive implications.
4.21%
G&A change of 4.21% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-30.50%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
43.24%
Other expenses change of 43.24% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
7.44%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.51%. Jim Chanos would check for waste.
7.00%
Total costs growth 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 5.06%. Guy Spier would scrutinize spending.
-21.09%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is -13.16%. Seth Klarman would investigate advantages.
7.03%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.03%. Jim Chanos would check for overinvestment.
-625.01%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 5.35%. Seth Klarman would investigate causes.
-597.86%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 1.58%. Seth Klarman would investigate causes.
-15.44%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 10.77%. Seth Klarman would investigate causes.
-9.48%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 21.29%. Seth Klarman would investigate causes.
-1562.95%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is -10.92%. Seth Klarman would investigate advantages.
-146.52%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 1.84%. Seth Klarman would investigate causes.
-133.77%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is -2.53%. Seth Klarman would investigate causes.
129.80%
Tax expense change of 129.80% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-117.73%
Net income decline while Drug Manufacturers - Specialty & Generic median is -3.36%. Seth Klarman would investigate causes.
-106.48%
Net margin decline while Drug Manufacturers - Specialty & Generic median is -0.74%. Seth Klarman would investigate causes.
-120.58%
EPS decline while Drug Manufacturers - Specialty & Generic median is -53.76%. Seth Klarman would investigate causes.
-123.71%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -70.25%. Seth Klarman would investigate causes.
-1.20%
Share count reduction while Drug Manufacturers - Specialty & Generic median is 3.52%. Seth Klarman would investigate strategy.
-1.20%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 3.52%. Seth Klarman would investigate strategy.